RxDoctor Payments Data

Dhaval Shah, MD

Interventional Cardiology · Tempe, AZNPI 1588975643

Payments from drug & device makers

$6,364in general payments, 2019–2025

Across 273 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Heartflow, Inc.$735
  • Amgen$376
  • Boehringer Ingelheim$371
  • Boston Scientific$370
  • Pfizer$312
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,364100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,364 in reported general payments places this provider in the 30th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$206,108
Medicare patients
548
Services billed
2,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban256$231,544
XareltoRivaroxaban100$96,987
EntrestoSacubitril/Valsartan57$50,864
JardianceEmpagliflozin37$32,447
Repatha SureclickEvolocumab11$13,881
Repatha SyringeEvolocumab25$13,556
FarxigaDapagliflozin Propanediol15$11,980
BrilintaTicagrelor13$11,174
NexlizetBempedoic Acid/Ezetimibe18$11,085
VascepaIcosapent Ethyl18$9,653
Atorvastatin Calcium340$2,422
Diltiazem 24hr Er (La)Diltiazem Hcl43$1,838
Rosuvastatin Calcium167$1,827
Amlodipine Besylate322$1,729
Metoprolol Succinate194$1,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$312$231,544256 claims
Johnson & JohnsonXarelto$148$96,987100 claims
NovartisEntresto$1,007$50,86457 claims
Boehringer IngelheimJardiance$371$32,44737 claims
AstraZenecaFarxiga, Brilinta$229$23,15428 claims
Esperion Therapeutics, Inc.Nexlizet$69$11,08518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Tempe

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →